CalciMedica’s (CALC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $16.00 price objective on the stock.

CalciMedica Price Performance

Shares of CalciMedica stock opened at $1.94 on Thursday. CalciMedica has a 1 year low of $1.43 and a 1 year high of $6.02. The business has a 50 day moving average price of $1.81 and a 200 day moving average price of $2.56. The company has a market capitalization of $27.11 million, a P/E ratio of -1.80 and a beta of 1.24.

CalciMedica (NASDAQ:CALC) last released its earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. As a group, research analysts expect that CalciMedica will post -2.21 EPS for the current fiscal year.

Institutional Trading of CalciMedica

Several large investors have recently modified their holdings of CALC. First Manhattan CO. LLC. bought a new stake in shares of CalciMedica in the 1st quarter worth about $25,000. 180 Wealth Advisors LLC bought a new position in CalciMedica during the 1st quarter worth $31,000. Cetera Investment Advisers grew its position in shares of CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after acquiring an additional 4,566 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in CalciMedica in the 1st quarter worth about $45,000. Finally, Wealthedge Investment Advisors LLC acquired a new stake in CalciMedica in the 4th quarter valued at approximately $98,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.